Jordi Lopez-Tremoleda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jordi Lopez-Tremoleda has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Marzena Wylezinska-Arridge
Biological Imaging Center, MRC Clinical Sciences Centre, Imperial College of London
2 shared publications W. Gsell
2 shared publications- Willy Gsell
Biological Imaging Centre (BIC), Medical Research Council (MRC) Clinical Science Centre, Imperial College London, Hammersmith Campus, Cyclotron Building, Du Cane Road, London, W12 0NN, UK
2 shared publications A H W R Simpson
1 shared publicationA J Martin
1 shared publicationA. Schrantee
1 shared publication
Latest Publications
- 1 December 2014
- Published by Elsevier in Atherosclerosis
- Vol. 237 (2) , e11
Longitudinal predictive analysis of vulnerable plaques in a mouse model of atherosclerosis
- 1 December 2014
- Published by Elsevier in Atherosclerosis
- Vol. 237 (2) , e11
Longitudinal predictive analysis of vulnerable plaques in a mouse model of atherosclerosis
- 1 December 2012
- Vol. 12 (4) , 241-53
Assessment of a preclinical model for studying the survival and engraftment of human stem cell derived osteogenic cell populations following orthotopic implantation.
Preclinical studies with osteoprogenitor cells derived from human embryonic stem cells (hESC) do not lead to substantial bone regeneration in vivo. The degree of survival following implantation might play a role in their long term efficiency. We investigated the initial engraftment of hESCs-derived cells during two weeks post-implantation and compared it to such response for adult bone marrow stromal cells (hBMSC)-derived osteoprogenitor cells. hBMSC and H9-hES cells pre-treated with osteogenic factors were implanted into a calvarial defect in both adult WT and nude rats. At days 7 and 14 post-implantation, samples were analysed for persistence of implanted cells, initiation of regeneration of host bone, angiogenesis and apoptosis. At day 7, hESC and hBMSC were detected within defects in both rat strains. By day 14 human cells were only detected in immune-deficient rats whilst still maintaining an osteoblastic phenotype and engendered a significant increase in bone formation. In WT animals, the participation of implanted cells was very limited due to their poor survival. This study demonstrates the ability of hESC and hBMSC derived osteoprogenitor cells to survive transplantation, to engraft and to develop an osteogenic phenotype during the early stage following implantation, validating the appropriate preclinical model.
- 1 December 2012
- Vol. 12 (4) , 241-53
Assessment of a preclinical model for studying the survival and engraftment of human stem cell derived osteogenic cell populations following orthotopic implantation.
Preclinical studies with osteoprogenitor cells derived from human embryonic stem cells (hESC) do not lead to substantial bone regeneration in vivo. The degree of survival following implantation might play a role in their long term efficiency. We investigated the initial engraftment of hESCs-derived cells during two weeks post-implantation and compared it to such response for adult bone marrow stromal cells (hBMSC)-derived osteoprogenitor cells. hBMSC and H9-hES cells pre-treated with osteogenic factors were implanted into a calvarial defect in both adult WT and nude rats. At days 7 and 14 post-implantation, samples were analysed for persistence of implanted cells, initiation of regeneration of host bone, angiogenesis and apoptosis. At day 7, hESC and hBMSC were detected within defects in both rat strains. By day 14 human cells were only detected in immune-deficient rats whilst still maintaining an osteoblastic phenotype and engendered a significant increase in bone formation. In WT animals, the participation of implanted cells was very limited due to their poor survival. This study demonstrates the ability of hESC and hBMSC derived osteoprogenitor cells to survive transplantation, to engraft and to develop an osteogenic phenotype during the early stage following implantation, validating the appropriate preclinical model.
- Open Access
- 1 January 2012
- Published by Springer Nature in EJNMMI Research
- Vol. 2 (1) , 44
Anaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare
The implementation of imaging technologies has dramatically increased the efficiency of preclinical studies, enabling a powerful, non-invasive and clinically translatable way for monitoring disease progression in real time and testing new therapies. The ability to image live animals is one of the most important advantages of these technologies. However, this also represents an important challenge as, in contrast to human studies, imaging of animals generally requires anaesthesia to restrain the animals and their gross motion. Anaesthetic agents have a profound effect on the physiology of the animal and may thereby confound the image data acquired. It is therefore necessary to select the appropriate anaesthetic regime and to implement suitable systems for monitoring anaesthetised animals during image acquisition. In addition, repeated anaesthesia required for longitudinal studies, the exposure of ionising radiations and the use of contrast agents and/or imaging biomarkers may also have consequences on the physiology of the animal and its response to anaesthesia, which need to be considered while monitoring the animals during imaging studies. We will review the anaesthesia protocols and monitoring systems commonly used during imaging of laboratory rodents. A variety of imaging modalities are used for imaging rodents, including magnetic resonance imaging, computed tomography, positron emission tomography, single photon emission computed tomography, high frequency ultrasound and optical imaging techniques such as bioluminescence and fluorescence imaging. While all these modalities are implemented for non-invasive in vivo imaging, there are certain differences in terms of animal handling and preparation, how the monitoring systems are implemented and, importantly, how the imaging procedures themselves can affect mammalian physiology. The most important and critical adverse effects of anaesthetic agents are depression of respiration, cardiovascular system disruption and thermoregulation. When anaesthetising rodents, one must carefully consider if these adverse effects occur at the therapeutic dose required for anaesthesia, if they are likely to affect the image acquisitions and, importantly, if they compromise the well-being of the animals. We will review how these challenges can be successfully addressed through an appropriate understanding of anaesthetic protocols and the implementation of adequate physiological monitoring systems.
- 1 January 2012
- Published by Springer Nature in EJNMMI Research
- Vol. 2 (1) , 44
Open AccessAnaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare
The implementation of imaging technologies has dramatically increased the efficiency of preclinical studies, enabling a powerful, non-invasive and clinically translatable way for monitoring disease progression in real time and testing new therapies. The ability to image live animals is one of the most important advantages of these technologies. However, this also represents an important challenge as, in contrast to human studies, imaging of animals generally requires anaesthesia to restrain the animals and their gross motion. Anaesthetic agents have a profound effect on the physiology of the animal and may thereby confound the image data acquired. It is therefore necessary to select the appropriate anaesthetic regime and to implement suitable systems for monitoring anaesthetised animals during image acquisition. In addition, repeated anaesthesia required for longitudinal studies, the exposure of ionising radiations and the use of contrast agents and/or imaging biomarkers may also have consequences on the physiology of the animal and its response to anaesthesia, which need to be considered while monitoring the animals during imaging studies. We will review the anaesthesia protocols and monitoring systems commonly used during imaging of laboratory rodents. A variety of imaging modalities are used for imaging rodents, including magnetic resonance imaging, computed tomography, positron emission tomography, single photon emission computed tomography, high frequency ultrasound and optical imaging techniques such as bioluminescence and fluorescence imaging. While all these modalities are implemented for non-invasive in vivo imaging, there are certain differences in terms of animal handling and preparation, how the monitoring systems are implemented and, importantly, how the imaging procedures themselves can affect mammalian physiology. The most important and critical adverse effects of anaesthetic agents are depression of respiration, cardiovascular system disruption and thermoregulation. When anaesthetising rodents, one must carefully consider if these adverse effects occur at the therapeutic dose required for anaesthesia, if they are likely to affect the image acquisitions and, importantly, if they compromise the well-being of the animals. We will review how these challenges can be successfully addressed through an appropriate understanding of anaesthetic protocols and the implementation of adequate physiological monitoring systems.
- Open Access
- 1 January 2012
- Published by Edicions de la Universitat de Barcelona in Revista de Bioética y Derecho
- No. 24,p. 61-72
Comentarios sobre la Directiva Europea 2010/63/EU para la protección de animales de laboratorio
El 20 de Octubre del 2010 se publico la nueva Directiva Europea 2010/63/EU sobre la protección de los animales utilizados en procedimientos científicos. Dicha publicación en el Diario Oficial de la Unión Europea supone el inicio de su tramitación para su entrada en vigor como ley Europea. Los países miembros tienen ahora un periodo de dos años para implementar dicha directiva como documento legal asegurando su completa entrada en vigor para Enero del 2013. En este artículo se realiza un análisis comparativo de la nueva Directiva 2010/63/EU y la normativa actual vigente en el Reino Unido, referente mundial en el área de protección de animales de laboratorio. La nueva Directiva reconoce la importancia de la utilización de animales de experimentación en los avances científicos, pero reforzando la defensa y el respeto del valor intrínseco del ser animal. En este sentido la Directiva representa un importante avance para la protección del bienestar animal en todos los estados miembros, con el objetivo de armonizar la legislación vigente. Si bien varios países ya disponen de una legislación bastante progresiva, la implementación de la nueva directiva representa una excelente oportunidad para asentar y/o homogeneizar criterios de alto estándar de protección del bienestar animal en todos los países miembros, reforzando así el compromiso de la Unión Europea con la investigación científica y el respeto al bienestar de los animales de experimentación.
- 1 January 2012
- Published by Edicions de la Universitat de Barcelona in Revista de Bioética y Derecho
- No. 24,p. 61-72
Open AccessComentarios sobre la Directiva Europea 2010/63/EU para la protección de animales de laboratorio
El 20 de Octubre del 2010 se publico la nueva Directiva Europea 2010/63/EU sobre la protección de los animales utilizados en procedimientos científicos. Dicha publicación en el Diario Oficial de la Unión Europea supone el inicio de su tramitación para su entrada en vigor como ley Europea. Los países miembros tienen ahora un periodo de dos años para implementar dicha directiva como documento legal asegurando su completa entrada en vigor para Enero del 2013. En este artículo se realiza un análisis comparativo de la nueva Directiva 2010/63/EU y la normativa actual vigente en el Reino Unido, referente mundial en el área de protección de animales de laboratorio. La nueva Directiva reconoce la importancia de la utilización de animales de experimentación en los avances científicos, pero reforzando la defensa y el respeto del valor intrínseco del ser animal. En este sentido la Directiva representa un importante avance para la protección del bienestar animal en todos los estados miembros, con el objetivo de armonizar la legislación vigente. Si bien varios países ya disponen de una legislación bastante progresiva, la implementación de la nueva directiva representa una excelente oportunidad para asentar y/o homogeneizar criterios de alto estándar de protección del bienestar animal en todos los países miembros, reforzando así el compromiso de la Unión Europea con la investigación científica y el respeto al bienestar de los animales de experimentación.
- Open Access
- 24 December 2011
- Published by Springer Nature in Psychopharmacology
- Vol. 221 (2) , 329-339
Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are increasingly used for the treatment of depression in children. Limited data are, however, available on their effects on brain development and their efficacy remains debated. Moreover, previous experimental studies are seriously hampered in their clinical relevance. The aim of the present study was to investigate putative age-related effects of a chronic treatment with fluoxetine (5 mg/kg, either orally or i.p. for 3 weeks, 1 week washout) using conventional methods (behavioral testing and binding assay using [123I]β-CIT) and a novel magnetic resonance imaging (MRI) approach. Behavior was assessed, as well as serotonin transporter (SERT) availability and function through ex vivo binding assays and in vivo pharmacological MRI (phMRI) with an acute fluoxetine challenge (10 mg/kg oral or 5 mg/kg i.v.) in adolescent and adult rats. Fluoxetine caused an increase in anxiety-like behavior in treated adult, but not adolescent, rats. On the binding assays, we observed increased SERT densities in most cortical brain regions and hypothalamus in adolescent, but not adult, treated rats. Finally, reductions in brain activation were observed with phMRI following treatment, in both adult and adolescent treated animals. Collectively, our data indicate that the short-term effects of fluoxetine on the 5-HT system may be age-dependent. These findings could reflect structural and functional rearrangements in the developing brain that do not occur in the matured rat brain. phMRI possibly will be well suited to study this important issue in the pediatric population.
- 24 December 2011
- Published by Springer Nature in Psychopharmacology
- Vol. 221 (2) , 329-339
Open AccessAge-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are increasingly used for the treatment of depression in children. Limited data are, however, available on their effects on brain development and their efficacy remains debated. Moreover, previous experimental studies are seriously hampered in their clinical relevance. The aim of the present study was to investigate putative age-related effects of a chronic treatment with fluoxetine (5 mg/kg, either orally or i.p. for 3 weeks, 1 week washout) using conventional methods (behavioral testing and binding assay using [123I]β-CIT) and a novel magnetic resonance imaging (MRI) approach. Behavior was assessed, as well as serotonin transporter (SERT) availability and function through ex vivo binding assays and in vivo pharmacological MRI (phMRI) with an acute fluoxetine challenge (10 mg/kg oral or 5 mg/kg i.v.) in adolescent and adult rats. Fluoxetine caused an increase in anxiety-like behavior in treated adult, but not adolescent, rats. On the binding assays, we observed increased SERT densities in most cortical brain regions and hypothalamus in adolescent, but not adult, treated rats. Finally, reductions in brain activation were observed with phMRI following treatment, in both adult and adolescent treated animals. Collectively, our data indicate that the short-term effects of fluoxetine on the 5-HT system may be age-dependent. These findings could reflect structural and functional rearrangements in the developing brain that do not occur in the matured rat brain. phMRI possibly will be well suited to study this important issue in the pediatric population.
- Open Access
- 1 January 2011
- Published by Springer Nature in EJNMMI Research
- Vol. 1 (1) , 11
Imaging technologies for preclinical models of bone and joint disorders
Preclinical models for musculoskeletal disorders are critical for understanding the pathogenesis of bone and joint disorders in humans and the development of effective therapies. The assessment of these models primarily relies on morphological analysis which remains time consuming and costly, requiring large numbers of animals to be tested through different stages of the disease. The implementation of preclinical imaging represents a keystone in the refinement of animal models allowing longitudinal studies and enabling a powerful, non-invasive and clinically translatable way for monitoring disease progression in real time. Our aim is to highlight examples that demonstrate the advantages and limitations of different imaging modalities including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging. All of which are in current use in preclinical skeletal research. MRI can provide high resolution of soft tissue structures, but imaging requires comparatively long acquisition times; hence, animals require long-term anaesthesia. CT is extensively used in bone and joint disorders providing excellent spatial resolution and good contrast for bone imaging. Despite its excellent structural assessment of mineralized structures, CT does not provide in vivo functional information of ongoing biological processes. Nuclear medicine is a very promising tool for investigating functional and molecular processes in vivo with new tracers becoming available as biomarkers. The combined use of imaging modalities also holds significant potential for the assessment of disease pathogenesis in animal models of musculoskeletal disorders, minimising the use of conventional invasive methods and animal redundancy.
- 1 January 2011
- Published by Springer Nature in EJNMMI Research
- Vol. 1 (1) , 11
Open AccessImaging technologies for preclinical models of bone and joint disorders
Preclinical models for musculoskeletal disorders are critical for understanding the pathogenesis of bone and joint disorders in humans and the development of effective therapies. The assessment of these models primarily relies on morphological analysis which remains time consuming and costly, requiring large numbers of animals to be tested through different stages of the disease. The implementation of preclinical imaging represents a keystone in the refinement of animal models allowing longitudinal studies and enabling a powerful, non-invasive and clinically translatable way for monitoring disease progression in real time. Our aim is to highlight examples that demonstrate the advantages and limitations of different imaging modalities including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging. All of which are in current use in preclinical skeletal research. MRI can provide high resolution of soft tissue structures, but imaging requires comparatively long acquisition times; hence, animals require long-term anaesthesia. CT is extensively used in bone and joint disorders providing excellent spatial resolution and good contrast for bone imaging. Despite its excellent structural assessment of mineralized structures, CT does not provide in vivo functional information of ongoing biological processes. Nuclear medicine is a very promising tool for investigating functional and molecular processes in vivo with new tracers becoming available as biomarkers. The combined use of imaging modalities also holds significant potential for the assessment of disease pathogenesis in animal models of musculoskeletal disorders, minimising the use of conventional invasive methods and animal redundancy.